Center Book Partners LP Biomarin Pharmaceutical Inc Transaction History

Center Book Partners LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$85.07 - $94.48 $236,154 - $262,276	-2,776 Reduced 20.86%	10,534 $932,000
Q2 2023 Aug 14, 2023	BUY	$86.68 - $100.3 $378,358 - $437,809	4,365 Added 48.8%	13,310 $1.15 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $44,484 - $59,455	507 Added 6.01%	8,945 $869,000
Q4 2022 Feb 13, 2023	SELL	$80.93 - $108.63 $168,253 - $225,841	-2,079 Reduced 19.77%	8,438 $873,000
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $155,693 - $183,701	1,895 Added 21.98%	10,517 $892,000
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $105,790 - $128,537	1,480 Added 20.72%	8,622 $715,000
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $190,676 - $237,935	-2,567 Reduced 26.44%	7,142 $551,000
Q4 2021 Feb 11, 2022	BUY	$71.72 - $91.47 $696,329 - $888,082	9,709 New	9,709 $858,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Center Book Partners LP, based on Form 13F filings with the SEC.

Stay updated on Center Book Partners LP with notifications on news.